Figure 7.

The effect of veltuzumab pre-dosing and consolidation therapy on a veltuzumab-bsMAb pretargeting procedure. (A) Administering 1.0 mg of veltuzumab 1 day before the injection of the veltuzumab bsMAb reduces efficacy of the pretargeting procedure using 0.25 mCi of the ⁹⁰Y-hapten-peptide, despite the use of additional veltuzumab therapy after the pretargeted ⁹⁰Y-hapten peptide was given. (B) minimizing the veltuzumab pre-dose to 0.25 mg restores the anti-tumor effects of the pretargeting procedure, even improving it in this study. (C) Adding a full veltuzumab consolidation therapy after the pretargeted therapy (i.e., 1.0 mg veltuzumab starting 1 week after the ⁹⁰Y-hapten peptide, followed by 3 weekly doses of 0.5 mg veltuzumab) improves response, even when animals were pre-dosed with 0.25 mg veltuzumab.